Articles Published in 2008

Pharm-Olam Growth at Record Pace in 2007

Thursday, January 24, 2008 03:16 PM

Houston-based contract research organization (CRO) Pharm-Olam International reported record revenue growth in 2007, signing $100 million in new contracts signed in the 12 months.

More... »

Type I Diabetes Drug See Positive Results in Phase II

Thursday, January 24, 2008 10:11 AM

Diamyd Medical (formerly issued positive long-term results from a phase IIb trial of Diamyd, GAD-65), recombinant glutamic acid decarboxylase (GAD) delivered with alum for injection, for the treatment of type I diabetes. This randomized study enrolled seventy pediatric and adolescent subjects in Sweden.

More... »

Recent Industry Personnel Changes

Wednesday, January 23, 2008 09:46 AM

Contract Research

More... »

Kendle Looking to Grow Phase I Business

Monday, January 21, 2008 03:10 PM

Cincinnati-based CRO Kendle is expanding its phase I business with the appointment of Philip Davies, a 20-year industry veteran in early stage research, and made another key hire to grow its Asia-Pacific operations.

More... »

CWWeekly January 14th Issue 2008

Friday, January 18, 2008 05:01 PM

Top News

More... »

Negative or Positive Trial Results?

Thursday, January 17, 2008 02:19 PM

There’s some great quotes in the Wall Street Journal’s story about the New England Journal of Medicine’s assertion that effectiveness of antidepressants has been exaggerated by selective publication of positive clinical trial results.

More... »

CenterWatch Monthly January 2008 Issue

Wednesday, January 16, 2008 01:21 PM

2007 Year in Review:  A Year of CRO Consolidation and Global Expansion

More... »

2007 Year in Review: A Year of CRO Consolidation and Global Expansion

Wednesday, January 16, 2008 12:00 AM

2007 saw activity intensify in regions such as Latin America, Asia and Eastern Europe. In 2006, only a handful of sponsors and CROs had toeholds in India and China. This year, a flurry of expansions took place in those areas as the entire clinical trials industry seemed to be jockeying for the potential R&D windfalls predicted.

More... »

Going Mad for CROs

Tuesday, January 15, 2008 10:24 AM

Public, global contract research organizations (CROs) are having a great run with stock prices soaring and their global growth story intact. The sector got additional validation Jan. 14 when “Mad Money” host Jim Cramer featured the niche. In general, star stock picker Cramer got the story straight on CROs, even though a few times he mispronounced company names. That happens, but at least he got the stock symbols right. And that is what counts. You can watch a replay of the episode here.

More... »

Non-Hodgkin's Lymphoma Drug Misses Primary Endpoint

Tuesday, January 15, 2008 07:20 AM

Genitope reported negative results from a phase III trial of MyVax, a patient-specific immunotherapy, for the treatment of previously untreated follicular B-cell non-Hodgkin’s lymphoma (fNHL). The subjects enrolled in this double-blind, randomized, controlled clinical trial first received chemotherapy to reduce their tumor burden, followed by a six-month rest period.

More... »